The Pharmacy That Makes the Medicine Itself
Compounding pharmacies prepare medicines tailored to individual patients, operating under an exemption from the approval requirements applying to manufactured drugs. Where that exemption ends has been decided by a disaster.
The Practice and the Exemption
Compounding is the preparation of a medicine by combining or altering ingredients to meet the needs of an individual patient. A pharmacist might prepare a liquid formulation for a child who cannot swallow a tablet, remove a dye a patient is allergic to, or combine ingredients into a topical preparation.
Compounded medicines are not approved by regulators. They are not tested for safety and efficacy, do not carry approved labelling, and are not manufactured under the standards applying to commercial products.
They are permitted because a physician prescribing for a specific patient with a specific need requires a product that no manufacturer makes, and requiring approval for a one off preparation would make it impossible.
Where the Line Was Always Blurred
The exemption assumes small scale preparation for identified patients. The commercial temptation is to produce in volume.
A facility preparing thousands of identical units and shipping them across state lines to hospitals and clinics is manufacturing, whatever the licence says. It competes with approved products, avoids the cost of approval, and operates outside the manufacturing quality standards that approval brings.
Regulators and compounders disputed the boundary for decades, with jurisdictional arguments complicated by the fact that pharmacy practice is regulated by states and drug manufacturing by the federal government.
The exemption exists because a patient sometimes needs something no manufacturer makes. It becomes dangerous at exactly the point where the compounder is making the same thing repeatedly, because that is manufacturing and the quality systems that go with manufacturing are not in place.
The Event That Settled It
In 2012 a compounding facility in Massachusetts shipped contaminated steroid injections to clinics across the country. The product was contaminated with fungus, and the resulting outbreak of fungal meningitis killed dozens of people and sickened hundreds more.
Investigation found conditions that would not have been tolerated in a manufacturing facility, at an operation producing large volumes of a sterile injectable and distributing nationally under a pharmacy licence.
The failure was jurisdictional as much as operational. State pharmacy regulators were not equipped to oversee sterile manufacturing at scale, and federal authority over an entity licensed as a pharmacy was contested.
The Framework That Followed
Legislation in 2013 created a two tier structure that remains the operative framework.
| Traditional Compounding | Outsourcing Facility | |
|---|---|---|
| Requires a patient specific prescription | Yes | No |
| May produce in anticipation of orders | Limited | Yes |
| Primary oversight | State boards of pharmacy | Federal registration and inspection |
| Manufacturing quality standards | Pharmacy standards | Current good manufacturing practice |
The second category was created specifically so that facilities producing at scale could do so lawfully, under federal inspection and manufacturing quality requirements, without needing approval for each product.
Registration is voluntary, which is the structural weakness. A facility that stays within the traditional definition remains under state oversight, and the incentive to register is commercial access to hospital customers rather than any legal compulsion.
The Commercial Tension
Compounders compete with approved products in several areas, and the disputes are ongoing.
The clearest arise where a compounded version of an approved drug is substantially cheaper. Compounding an approved drug is generally prohibited where the compounded version is essentially a copy, and permitted where the drug is in shortage, which creates a boundary that shifts with supply conditions.
Shortages of high demand medicines have produced exactly this situation, with compounded versions filling gaps, manufacturers objecting, and regulators issuing guidance as shortage status changes. Patients caught in that cycle discover that the availability and legality of their medicine depends on a list that is updated periodically.
What a Patient Should Understand
The practical points are narrow and important.
A compounded medicine has not been evaluated for safety or efficacy, and its potency and purity depend entirely on the practices of the facility that made it.
Sterile preparations, meaning injectables and ophthalmic products, carry substantially higher risk than oral or topical preparations, because contamination has severe consequences and sterility cannot be verified by looking.
Whether the facility is federally registered and inspected is knowable, and for any sterile product it is the most useful question to ask.
The Bottom Line
Compounding fills real gaps for patients whose needs no approved product meets, and it operates under an exemption from the testing and manufacturing standards that approval imposes. That exemption was designed for individual preparation and was used for national scale production, which killed people in 2012 and produced the two tier framework that exists now. The remaining weakness is that entering the inspected tier is voluntary, which means the strongest protection applies only to facilities that chose it.